Skip to main content
. Author manuscript; available in PMC: 2013 May 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2011 Sep 29;18(5):731–738. doi: 10.1016/j.bbmt.2011.09.007

Table 2.

Comparison of Variables in Responders and Nonresponders

Variable Responders (n = 9) Nonresponders (n = 4) P Value
Demographic factors
 Age, years, median (range) 6 (1.42-43) 24.7 (0.92-66) .99
 Pediatric, n (%) 6 (66.66) 2 (50.0) .99
 GVHD, n (%) 7 (77.78) 3 (75) .99
 Acute renal failure before CMX001 initiation, n (%) 4 (44.4) 2 (50) .99
 Time to infection after HCT, days, median (range) 105 (17-720) 45 (15-161) .70
Pretreatment factors
 Days on cidofovir before CMX001 initiation, median (range) 34 (7-90) 21 (5-21) .18
 Adenovirus, log10 VL at cidofovir initiation, median (range) 4.57 (2.00-8.04) 5.5 (4.14-6.19) .50
 Adenovirus, log10 VL at CMX001 initiation, median (range) 5.06 (2.00-7.81) 5.1 (4.33-6.65) .99
 ALC at CMX001 initiation, median (range) 300 (7-1500) 200 (90-400) .70
 ALC <300 at CMX001 initiation, n (%) 4 (44.4) 2 (50) .99
Response to treatment
 Total CMX001 exposure, days, median (range) 14 (6-72) 23.5 (15-34.7) .70
 Adenovirus, log10 VL after 4 weeks of CMX001, median (range) 2.85 (0-4.77) 5.29 (2.48-6.78) .07